Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 3

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 3
---
 in operating assets and liabilities: 

    Trade accounts payable and accrued liabilities 
     (332,580) 
     (10,091)
  
    Prepaid expenses 
     (17,414) 
     (87,100)
  
    Net cash flows used in operating activities 
    $(1,559,577) 
    $(3,462,258)

    Financing activities: 

    Payments under related party line of credit 
     -  
     (101,000)
  
    Payments to related party 
     -  
     (519,475)
  
    Borrowings from related party 
     -  
     132,438 
  
    Proceeds from sale of common stock 
     1,047,769  
     5,832,973 
  
    Net cash flows provided by financing activities 
     1,047,769  
     5,344,936 

    Net change in cash 
     (511,808) 
     1,882,678 
  
    Cash, beginning of period 
     1,266,131  
     1,231 
  
    Cash, end of period 
    $754,323  
    $1,883,909 
  
    Supplemental disclosure of cash flow information 

    Cash paid for interest 
     -  
     - 
  
    Cash paid for taxes 
     -  
     - 

See
notes to condensed unaudited financial statements

6

TELOMIR
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

JUNE
30, 2025

(Unaudited)

Note
1. Description of business and summary of significant accounting policies:

Overview

Telomir-1
is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative
stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help
protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s
disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type
2 Diabetes, cancer, and Alzheimer’s disease. Oxidative stress